A Cold Shower For Viagra: How Congress Can Chill A Market
This article was originally published in RPM Report
Executive Summary
Pfizer, Lilly and the other marketers of drugs for erectile dysfunction are kicked out of Medicare and Medicaid. Viagra and the other brands may be the first victims of the backlash against DTC advertising. They are also a case study in how Congress can--and well--make mischief under the Medicare program.
You may also be interested in...
Second-Guessing FDA: CMS' Expanding Regulatory Role
Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA's jurisdiction-and the health care reform implementation is bringing more of those cases to the fore.
Second-Guessing FDA: CMS' Expanding Regulatory Role
Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA's jurisdiction-and the health care reform implementation is bringing more of those cases to the fore.
Health Care Reform and Business Development: 10 Reasons It Matters
The drama of the US health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.